Cargando…

Beneficial Effect of Edoxaban on Preventing Atrial Fibrillation and Coagulation by Reducing Inflammation via HBG1/HBD Biomarkers

Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia. The effectiveness and mechanism of edoxaban in preventing stroke after atrial fibrillation remain unclear. Methods: The expressions of HBG1 and HBD in red blood cells were tested in AF. Sixty C57B/6J mice were randomly divid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Chenguang, Wang, Xiang, Guo, Ying, Meng, Xuyang, Li, Yi, Xia, Chenxi, Meng, Lingbing, Dong, Min, Wang, Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204214/ https://www.ncbi.nlm.nih.gov/pubmed/35721103 http://dx.doi.org/10.3389/fphar.2022.904317

Ejemplares similares

Joint efficacy of the three biomarkers SNCA, GYPB and HBG1 for atrial fibrillation and stroke: Analysis via the support vector machine neural network
por: Wang, Xiang, et al.
Publicado: (2022)

Association of polymorphisms in the HBG1‐HBD intergenic region with HbF levels
por: Hu, Li, et al.
Publicado: (2020)

Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation
por: Lin, Shin-Yi, et al.
Publicado: (2021)

Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
por: Grymonprez, Maxim, et al.
Publicado: (2023)

Effectiveness and safety of edoxaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies
por: Alsultan, Mohammed M., et al.
Publicado: (2023)

Changes in plasma concentrations of edoxaban and coagulation biomarkers according to thromboembolic risk and atrial fibrillation type in patients undergoing catheter ablation: Subanalysis of KYU‐RABLE
por: Shinohara, Tetsuji, et al.
Publicado: (2020)

Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease
por: Fukamachi, Daisuke, et al.
Publicado: (2022)

Early experiences with edoxaban for stroke prevention in atrial fibrillation in the Southeast Asia region
por: Diaz, Alejandro Bimbo, et al.
Publicado: (2023)

Point-of-care testing of coagulation in patients treated with edoxaban
por: Härtig, Florian, et al.
Publicado: (2020)

Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation
por: Lee, So-Ryoung, et al.
Publicado: (2019)

Outcomes of On-Label Reduced-Dose Edoxaban in Patients With Atrial Fibrillation: The LEDIOS Registry
por: Kim, Ju Youn, et al.
Publicado: (2022)

Hemoptysis in Quadriplegia with Atrial Fibrillation Who Was Taking Edoxaban: a Case Report
por: Jeong, Hoyoung, et al.
Publicado: (2021)

Edoxaban Dosing Time Affects Blood Coagulation Inhibition in Rats
por: Nagata, Naoto, et al.
Publicado: (2021)

A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation
por: Patti, Giuseppe, et al.
Publicado: (2022)

Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients With Atrial Fibrillation and in Pressure Overload-Induced Mice
por: Suo, Ya, et al.
Publicado: (2019)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
por: Oyagüez, Itziar, et al.
Publicado: (2019)

Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure
por: Nabeta, Takeru, et al.
Publicado: (2021)

Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice
por: Choi, Eue-Keun, et al.
Publicado: (2021)

Pharmacological Inhibition of Serine Proteases to Reduce Cardiac Inflammation and Fibrosis in Atrial Fibrillation
por: Coppini, Raffaele, et al.
Publicado: (2019)

Inflammation and Coagulation are Two Interconnected Pathophysiological Pathways in Atrial Fibrillation Pathogenesis
por: Hazarapetyan, Lusine, et al.
Publicado: (2023)

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation
por: Acharya, Tushar, et al.
Publicado: (2015)

Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide
por: De Caterina, Raffaele, et al.
Publicado: (2017)

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial
por: Kato, Eri Toda, et al.
Publicado: (2016)

Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism
por: Stacy, Zachary A., et al.
Publicado: (2016)

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
por: Hohnloser, Stefan H, et al.
Publicado: (2019)

Edoxaban Versus Low-Molecular-Weight Heparin in Hospitalized COVID-19 Patients With Atrial Fibrillation
por: Olivera, Pável, et al.
Publicado: (2023)

Tissue-specific human beta-defensins (HBD)1, HBD2, and HBD3 secretion from human extra-placental membranes stimulated with Escherichia coli
por: Garcia-Lopez, Guadalupe, et al.
Publicado: (2010)

Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Wang, Yapeng, et al.
Publicado: (2023)

Update on anti-coagulation in atrial fibrillation
por: Kreuzer, J.
Publicado: (2011)

Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms
por: Geng, Meng, et al.
Publicado: (2020)

Beneficial Effects of Quercetin on Microcystin-LR Induced Tight Junction Defects
por: Zhou, Yuan, et al.
Publicado: (2021)

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)
por: De Caterina, Raffaele, et al.
Publicado: (2019)

An instrument to measure atrial fibrillation knowledge in Chinese patients: validation of the Jessa Atrial fibrillation Knowledge Questionnaire
por: Chang, Sijie, et al.
Publicado: (2023)

Diagnostic and Therapeutic Potential for HNP-1, HBD-1 and HBD-4 in Pregnant Women with COVID-19
por: Brancaccio, Mariarita, et al.
Publicado: (2022)

MIR29B mediates epigenetic mechanisms of HBG gene activation
por: Starlard‐Davenport, Athena, et al.
Publicado: (2019)

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
por: Miller, Jeffrey D, et al.
Publicado: (2016)

Corrigendum to: Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
Publicado: (2019)

Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min
por: Yin, Ophelia, et al.
Publicado: (2021)

Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care
por: Kirchhof, Paulus, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n5pnjggdvtasnqqgd51qr1u94k